Zobrazeno 1 - 10
of 39
pro vyhledávání: ''
Autor:
Joana Almeida, Conceição Santos, Maria João Martins, Carina Proença, Helena Oliveira, José Miguel P. Ferreira de Oliveira, Eduarda Fernandes
Publikováno v:
Pharmaceuticals, Vol 14, Iss 640, p 640 (2021)
Pharmaceuticals
Volume 14
Issue 7
Pharmaceuticals
Volume 14
Issue 7
New agents are demanded to increase the therapeutic options for osteosarcoma (OS). Although OS is the most common bone cancer in children and adolescents, it is considered a rare disorder. Therefore, finding adjuvant drugs has potential to advance th
Autor:
Mary J. Meegan, Daniela M. Zisterer, Darren Fayne, Niamh M. O’Boyle, Brendan Twamley, Azizah M. Malebari, Denise Coutinho Endringer, Elisangela Flavia Pimentel, Patrick M. Kelly, Seema M. Nathwani, Sara Noorani, Gloria Ana
Publikováno v:
Pharmaceuticals, Vol 14, Iss 169, p 169 (2021)
Pharmaceuticals
Volume 14
Issue 2
Pharmaceuticals
Volume 14
Issue 2
We report the synthesis and biochemical evaluation of compounds that are designed as hybrids of the microtubule targeting benzophenone phenstatin and the aromatase inhibitor letrozole. A preliminary screening in estrogen receptor (ER)-positive MCF-7
Autor:
Daniel Hänggi, Christoph Janiak, Donata Maciaczyk, Silke Neumann, Katharina Koch, Beatriz Giesen, Julia Tsiampali, Jaroslaw Maciaczyk
Publikováno v:
Pharmaceuticals, Vol 13, Iss 378, p 378 (2020)
Pharmaceuticals
Volume 13
Issue 11
Pharmaceuticals
Volume 13
Issue 11
Glioblastoma (GBM) is the most aggressive malignant primary brain tumour in adulthood. Despite strong research efforts current treatment options have a limited impact on glioma stem-like cells (GSCs) which contribute to GBM formation, progression and
Publikováno v:
Pharmaceuticals, Vol 13, Iss 413, p 413 (2020)
Pharmaceuticals
Pharmaceuticals
Non-small cell lung cancer (NSCLC) remains the most prevalent and one of the deadliest cancers worldwide. Despite recent success, there is still an urgent need for new therapeutic strategies. It is also becoming increasingly evident that combinatoria
Autor:
Benjamin Meder, Till Milde, Simay Ayhan, Martin Distel, Johannes Ridinger, Sara Najafi, Heike Peterziel, Jagoda K. Wrobel, Ina Oehme, Charlotte Gatzweiler, Damir Krunic, Olaf Witt, Frank Westermann
Publikováno v:
Pharmaceuticals, Vol 13, Iss 345, p 345 (2020)
Pharmaceuticals
Volume 13
Issue 11
Pharmaceuticals
Volume 13
Issue 11
The survival rate among children with relapsed neuroblastomas continues to be poor, and thus new therapeutic approaches identified by reliable preclinical drug testing models are urgently needed. Zebrafish are a powerful vertebrate model in preclinic
Autor:
Julio Sotelo, Roxana Magaña-Maldonado, Iannel Reyes-Vidal, Daniel Pérez-Pérez, Elda Georgina Chávez-Cortez
Publikováno v:
Pharmaceuticals, Vol 12, Iss 3, p 130 (2019)
Pharmaceuticals
Pharmaceuticals
Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Currently, treatment is ineffective and the median overall survival is 20.9 months. The poor prognosis of GBM is a consequence of several altered signaling pathways that favor
Autor:
Chan-Yen Kuo, Geng-Ruei Chang, Ming-Yang Tsai, Tzu-Chun Lin, Yu-Chen Wang, Huei-Jyuan Liao, Chung-Hung Chen, Wei-Li Lin
Publikováno v:
Molecules
Volume 26
Issue 15
Molecules, Vol 26, Iss 4683, p 4683 (2021)
Volume 26
Issue 15
Molecules, Vol 26, Iss 4683, p 4683 (2021)
Zotarolimus is a semi-synthetic derivative of rapamycin and an inhibitor of mammalian target of rapamycin (mTOR) signaling. Currently, zotarolimus is used to prolong the survival time of organ grafts, but it is also a novel immunosuppressive agent wi
Autor:
May Zie Koh, Swee Keong Yeap, Noorjahan Banu Alitheen, Lily Boo, Norlaily Mohd Ali, Wan Yong Ho
Publikováno v:
Pharmaceuticals
Volume 14
Issue 5
Pharmaceuticals, Vol 14, Iss 391, p 391 (2021)
Volume 14
Issue 5
Pharmaceuticals, Vol 14, Iss 391, p 391 (2021)
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype that promotes a higher risk of metastasis and cancer reoccurrence. Cisplatin is one of the potential anticancer drugs for treating TNBC. However, the occurrence of cisplatin
Publikováno v:
Pharmaceuticals, Vol 14, Iss 254, p 254 (2021)
Pharmaceuticals
Volume 14
Issue 3
Pages: 254
Pharmaceuticals
Volume 14
Issue 3
Pages: 254
Cancer is a complex devastating disease with enormous treatment challenges, including chemo- and radiotherapeutic resistance. Combination therapy demonstrated a promising strategy to target hard-to-treat cancers and sensitize cancer cells to conventi
Autor:
Margaret R. Dunne, Becky A.S. Bibby, Maria Davern, Breandán N. Kennedy, Amy M. Buckley, Stephen G. Maher, Jacintha O'Sullivan, Susan Kennedy
Publikováno v:
Pharmaceuticals, Vol 12, Iss 1, p 33 (2019)
Pharmaceuticals
Volume 12
Issue 1
Pharmaceuticals
Volume 12
Issue 1
Cisplatin (cis-diamminedichloroplatinum) is widely used for the treatment of solid malignancies
however, the development of chemoresistance hinders the success of this chemotherapeutic in the clinic. This study provides novel insights into the m
however, the development of chemoresistance hinders the success of this chemotherapeutic in the clinic. This study provides novel insights into the m